The POPSTAR II clinical trial, due to begin in early 2023 at multiple sites, will compare two cutting-edge treatments for men with advanced prostate cancer – lutetium PSMA (LuPSMA) therapy and stereotactic ablative radiotherapy (SABR). During a recent visit to Australia, Sheba’s Director General, Prof. Yitshak Kreiss, signed a letter of intent making Sheba an international partner for the new trial.
After visiting Israel, Peter Mac Chief Executive. Prof. Shelley Dolan described this latest agreement as another example of the growing international relationship between two leading institutions.
“The international expansion of this clinical trial will boost access for men to innovative new prostate cancer treatments,” Prof. Dolan explained. “Following the signing of an MOU between Peter Mac and Sheba Medical Center, it is fantastic to see that it is being implemented for the benefit of people with cancer internationally.”
The aforementioned MOU was signed in May when both organizations agreed to collaborate on innovation and commercialization opportunities, research and scientific collaborations, educational and training opportunities, fellowship programs, staff exchanges, and more.
Commenting on the new agreement, Professor Kreiss stressed: “We see our collaboration with Peter Mac as an important step toward strengthening our relationship with the Victorian Government in relation to innovation and clinical research. Peter Mac is an elite institution that is a leader in research and the development of novel treatments. It endeavors to change the future of medicine, mirroring Sheba’s vision via our ARC innovation center.”
Home to some of the world’s top experts in cancer research, and prostate cancer in particular, Sheba is proud to play a leading role in the development of advanced therapies for the benefit of patients worldwide.
